Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.55 |
| ▸ | TDO2 | P48775 | 14/20 | 0.55 |
| ▸ | IDO2 | Q6ZQW0 | 11/20 | 0.55 |
| ▸ | APAF1 | O14727 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26614249 | 0.92 | IDO1 (0.60) | IDO1TDO2IDO2APAF1MEN1 | |
| SCHEMBL26614101 | 0.85 | IDO1 (0.47) | IDO1TDO2IDO2APAF1MEN1 | |
| SCHEMBL30639067 | 0.85 | IDO1 (0.47) | IDO1TDO2IDO2APAF1MEN1 | |
| SCHEMBL26614233 | 0.81 | IDO1 (0.48) | IDO1TDO2IDO2APAF1MEN1 | |
| SCHEMBL26614267 | 0.79 | IDO1 (0.44) | IDO1TDO2IDO2APAF1MEN1 | |
| SCHEMBL26614116 | 0.78 | IDO1 (0.48) | IDO1TDO2IDO2APAF1MEN1 | |
| SCHEMBL31382844 | 0.77 | IDO1 (0.66) | IDO1TDO2IDO2APAF1MEN1 | |
| SCHEMBL26614171 | 0.77 | IDO1 (0.66) | IDO1TDO2IDO2APAF1MEN1 | |
| SCHEMBL26614227 | 0.77 | IDO1 (0.66) | IDO1TDO2IDO2APAF1MEN1 | |
| SCHEMBL26614195 | 0.77 | IDO1 (0.56) | IDO1TDO2IDO2APAF1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4514804-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | Viscient Bio, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119487031-A | Tryptanthrin derivatives and uses thereof | 威森特生物公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | IDO2, IDO1, TPSB2 | IDO1 2/4885TDO2 8/4885IDO2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.